Precision BioSciences Stock Rises On Early-stage CAR-T Trial Data -- MarketWatch
Precision BioSciences Stock Rises On Early-stage CAR-T Trial Data -- MarketWatch
DJ Precision BioSciences Stock Rises On Early-stage CAR-T Trial Data -- MarketWatch
DJ 精密生物科學庫存在早期 CAR-T 試驗數據上漲-市場觀察
Shares of Precision BioSciences Inc. (DTIL) are up 13% in premarket trading after it announced positive results from a small Phase 1 clinical trial for its chimeric antigen receptor (CAR) T cell therapy. Precision, which is developing the drug with a not-for-profit French pharmaceutical company Servier, tested the experimental therapy in patients with Non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. "These first-in-human data for PBCAR0191 suggest a tolerable safety profile and encouraging early evidence of clinical activity," Dr. Bijal Shah, an oncologist at the Moffitt Cancer Center in Tampa, Fla., and the trial's clinical investigator, said in a news release. Precision went public earlier this year; its stock is up 144% for the last three months. The S&P 500 has gained 5% during the same period.
精密生物科學公司（DTIL）的股份在上市前交易中上漲了 13%，該公司宣布了嵌合抗原受體（CAR）T 細胞療法的小型 1 期臨床試驗的積極結果。Precision 正在與非營利法國製藥公司 Servier 一起開發該藥物，對非霍奇金淋巴瘤和 B 細胞急性淋巴細胞白血病患者進行了實驗療法測試。佛羅里達州坦帕市莫菲特癌症中心的腫瘤科醫生 Bijal Shah 博士和該試驗的臨床研究人員在一份新聞稿中表示：「這些 PBCAR0191 的首次人體數據表明了可以容忍的安全性，並且令人鼓舞的臨床活動的早期證據。精準度在今年早些時候上市；在過去三個月中，其庫存量上漲了 144%。標普 500 在同一時期已經上漲了 5％。
-Jaimy Lee
-李在美
For more from MarketWatch: http://www.marketwatch.com/newsviewer
欲了解更多來自市場查看:http://www.marketwatch.com/newsviewer
(END) Dow Jones Newswires
(完) 道瓊斯通訊社
December 09, 2019 08:42 ET (13:42 GMT)
二零一九年十二月九日 08:42 歐洲時間 13:42
Copyright (c) 2019 Dow Jones & Company, Inc.
版權所有 (c) 2019 道瓊斯公司
譯文內容由第三人軟體翻譯。
